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Abstract
Inhalation anthrax is a rare but acute infectious disease following adsorption of Bacillus anthracis 
spores through the lungs. The disease has a high fatality rate if untreated, but early and correct 
diagnosis has a significant impact on case patient recovery. The early symptoms of inhalation 
anthrax are, however, non-specific and current anthrax diagnostics are primarily dependent upon 
culture and confirmatory real-time PCR. Consequently, there may be a significant delay in 
diagnosis and targeted treatment. Rapid, culture-independent diagnostic tests are therefore needed, 
particularly in the context of a large scale emergency response.
The aim of this study was to evaluate the ability of monoclonal antibodies to detect anthrax toxin 
proteins that are secreted early in the course of B. anthracis infection using a time-resolved 
fluorescence (TRF) immunoassay. We selected monoclonal antibodies that could detect protective 
antigen (PA), as PA83 and also PA63 and LF in the lethal toxin complex. The assay reliable 
detection limit (RDL) was 6.63 × 10−6 μM (0.551 ng/ml) for PA83 and 2.51 × 10−5 μM (1.58 
ng/ml) for PA63. Despite variable precision and accuracy of the assay, PA was detected in 9 out of 
10 sera samples from anthrax confirmed case patients with cutaneous (n=7), inhalation (n=2), and 
gastrointestinal (n=1) disease. Anthrax Immune Globulin (AIG), which has been used in treatment 
of clinical anthrax, interfered with detection of PA. This study demonstrates a culture-independent 
method of diagnosing anthrax through use of monoclonal antibodies to detect PA and LF in the 
lethal toxin complex.
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1. Introduction
Bacillus anthracis is an aerobic spore-forming gram-positive bacterium that is the causative 
agent of anthrax. Anthrax in humans can manifest in four different forms: cutaneous, 
gastrointestinal, inhalation or injection (Logan et al., 2011; Palmateer et al., 2013). 
Cutaneous anthrax is the most common form of the disease, accounting for 99% of cases 
worldwide but with a low fatality if treatment is available (Centers for Disease and 
Prevention, 2001; Logan et al., 2011). Ingestion of B. anthracis can result in either 
oropharangeal or gastrointestinal disease, with a variable mortality rate depending on how 
quickly treatment is started (Logan et al., 2011). Inhalation anthrax is rare but has a high 
mortality rate (89%) if not diagnosed early and treated promptly (Logan et al., 2011). In 
2001 anthrax spores were intentionally released in mailed letters in the United States, 
resulting in 22 cases (Logan et al., 2011). The mortality rate of inhalation anthrax was as 
high as 89% before 2001, but with advanced treatment and supportive care, the mortality 
rate was only 45% in 2001 (Jernigan et al., 2002). Injection anthrax is a more recent type of 
infection associated with intravenous drug users (Palmateer et al., 2013). Symptoms of 
injection anthrax is similar to cutaneous, but the infection may be in deeper tissues such as 
muscle and it can go systemic quickly (CDC, 2013).
Toxins released by B. anthracis play a major role in establishing and maintaining infection. 
Anthrax toxins consist of protective antigen (PA), lethal factor (LF), and edema factor (EF). 
Native PA is produced as a 83-kDa protein (PA83) that binds to host cell receptors, is 
cleaved and activated by cellular proteases to release a 20-kDa segment, leaving PA63 to 
form an oligomeric complex at the cell membrane (Young and Collier, 2007; Kintzer et al., 
2009). The PA63 complex binds up to four LF and EF molecules to form lethal toxin (LTx; 
PA63 + LF) or edema toxin (ETx; PA63 + EF) which may then be internalized into the cell 
to cause a cascade of cytotoxic effects (Young and Collier, 2007).
Anthrax is diagnosed by a variety of methods including: staining of specimens to visualize 
the organism, culture, PCR, and serology (Logan et al., 2011). Other methodologies for 
diagnosing anthrax have been reported in the literature and include those that detect anthrax 
toxins instead of the organism itself (Kobiler et al., 2006; Boyer et al., 2007; Rossi et al., 
2008; Tang et al., 2009; Oh et al., 2011; Dragan et al., 2012). Anthrax toxins are secreted 
early during the course of infection and therefore provide a more timely diagnosis than the 
use of immunoserology, which requires the production of antibodies by the immune system, 
or culture, which may take several days and requires appropriate laboratory facilities (Logan 
et al., 2011). Tang et al. previously described an immunoassay using both polyclonal and 
monoclonal antibodies in time-resolved fluorescence (TRF) immunoassay, a method that 
utilizes a high fluorescent nanoparticle (europium), to detect PA in sera to aid in diagnosis 
of anthrax (Tang et al., 2009).
The aim of this study was to evaluate antigen-specific monoclonal antibodies for use in 
culture independent assays capable of detecting PA83, PA63 and LTx in the early and 
convalescent stages of infection following treatment with antibiotics and immunotherapy. 
TRF was chosen to evaluate our collection monoclonal antibodies because of its higher 
sensitivity compared to ELISA.
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2. Materials and methods
2.1. Materials
Purified recombinant native protective antigen [83 kDa (1 μM=83μg/ml); PA83] was 
obtained from BEI Resources (Manassas, VA). Activated protective antigen [63 kDa (1 
μM=63μg/ml); PA63] and recombinant lethal factor [90 kDa (1 μM=90 μg/ml); LF] were 
obtained from List Biological Laboratories (Campbell, CA). Dissociation-enhanced 
lanthanide fluorescent immunoassay (DELFIA) buffer, wash concentrate, enhancement 
solution, Streptavidin Microtitration 96-well plates, Platewash, Plateshake, and Victor™ X4 
Multilabel Plate Reader were from Perkin-Elmer Life Sciences (Shelton, CT). Lethal toxin 
(LTx) was prepared by combining PA63 and LF in a 7:4 ratio. Anthrax Immune Globulin 
(AIG), an investigational product for anthrax treatment consisting primarily of anti-PA 
antibody, was previously acquired from Cangene (Winnipeg, MB, Canada).
2.2. Monoclonal Antibody Preparation, Selection, and Labeling
Mouse monoclonal anti-PA IgG antibodies (1 μM=150 μg/ml) were prepared in the Division 
of Scientific Resources at CDC as previously described (Boyer et al., 2007). Monoclonal 
anti-PA IgG AVR1046 was selected as the detector antibody (Li et al., 2008) and 
monoclonal anti-LF antibody, AVR1674, was selected for experiments for detection of LF 
in the LTx complex (Boyer et al., 2007). AVR1046 and AVR1674 were europium (Eu) 
labeled (Eu-AVR1046 and Eu-AVR1674) by Perkin-Elmer BioSignal Inc. (Montreal, QC, 
Canada). Four anti-PA mouse monoclonal antibodies were tested and AVR1162 was 
selected as the capture antibody based on its ability to bind PA83 and PA63 without 
competing with AVR1046, the detector antibody (data not shown). AVR1162 was 
biotinylated (Bio-AVR1162) in the Division of Scientific Resources at CDC with EZ-Link® 
Sulfo-NHS-Biotin (Pierce Biotechnology, Rockford, IL) following the manufacturer’s 
instructions.
2.3. Human Sera
Serum from 10 healthy human donors that had not been previously diagnosed with anthrax 
or received the anthrax vaccine was obtained from Tennessee Blood Services (Memphis, 
TN) for use in assay development. Sera were confirmed non-reactive for anti-PA IgG by 
ELISA before spiking experiments (Quinn et al., 2002; Semenova et al., 2012).
Serum samples from 10 healthy unvaccinated volunteers enrolled in an anthrax vaccine 
human clinical trial (Marano et al., 2008) and 10 patients confirmed with anthrax were 
tested to determine performance on clinical samples. Of the 10 human patients confirmed 
with disease, seven of the cases were cutaneous anthrax with sera samples drawn between 1 
and 8 days after symptoms onset (Boyer et al., 2011b). Two of the sera were from inhalation 
anthrax cases and the samples were collected two to eight days after symptoms onset. The 
sample from the patient with gastrointestinal anthrax was drawn 11 days after symptoms 
onset. All samples were taken prior to treatment with AIG. Methods for detection of LF and 
anti-PA IgG have been previously described (Boyer et al., 2011a; Semenova et al., 2012).
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Use of human serum used in the study were approved by the Centers for Disease Control 
and Prevention (CDC) Human Subjects Institutional Review Board (IRB).
2.4. Optimization of LTx complex detection assay
Ratios of capture and detector antibody pairs for PA were optimized using standard 
checkerboard titrations. Capture antibody Bio-AVR1162 was tested at concentrations 
ranging from 0.03 μg/mL to 32.0 μg/mL and the detector antibody Eu-AVR1046 was tested 
between 0.0078 μg/mL to 16.0 μg/mL. Based on the results of the experiment, the following 
assay procedure was used for all subsequent experiments. DELFIA Streptavidin 
Microtitration 96-well plate was washed with one cycle on the DELFIA Platewash. The 
capture antibody (24.0 μg/mL Bio-AVR1162) was added to the plate and then incubated at 
room temperature for 2.5 hours with shaking on the DELFIA Plateshake and then washed 
for two cycles. Test samples and controls were added in duplicate to the plate and then 
incubated for 1 hour at room temperature with shaking and then washed for 10 cycles. The 
detector antibody (1.0 μg/mL Eu-AVR1046) was added to the plate, incubated at room 
temperature for 1 hour with shaking and then washed for 10 cycles. After washing 200 μl 
DELFIA enhancement solution was added to each well and the plate was incubated for 10 
minutes at room temperature on low on the DELFIA Plateshake and then read on the 
Victor™ X4 Multilabel Plate Reader to determine the counts per second (CPS).
To determine if the formation LTx would interfere with PA63 detection and if LF could be 
detected in the LTx complex, pooled sera from 10 donors was spiked with 7:4 ratio of PA63 
to LF (0.5 μM PA63 and 0.286 μM LF). The master dilution mix was then serially 
transferred in 2-fold dilutions and pipetted into six rows on a DELFIA Streptavidin 
Microtitration 96-well plate in the sample addition step. For the first two rows 1.0 μg/mL 
Eu-AVR1046 was used as the detector antibody as described in 2.4. For the next two, 2.0 
μg/mL Eu-AVR1674 was used to detect LF present in LTx. The last two rows used a both 
1.0 μg/mL Eu-AVR1046 and 2.0 μg/mL Eu-AVR1674 to determine if the combination of 
these antibodies could provide an additive effect in detecting anthrax toxin. As a control, 
PA63 only was serially diluted in duplicate on the plate and probed with 1.0 μg/mL Eu-
AVR1046. This experiment was repeated independently seven times. The Student’s t-test 
was used to compare the different test conditions, a p-value≤0.05 was considered significant.
2.5. Limit of detection and quantification
Serum from each of 10 donors was pooled and spiked with 0.88 μM of either PA83 or PA63. 
The master dilution of the spiked sera was then serially transferred in 2-fold dilutions and 
tested in duplicate in 16 independent experiments for both PA83 and PA63. The TRF assay 
method was followed as described in section 2.4.
The measured counts per second were fit to a 5-Parameter Logistic (5-PL) model 
(Gottschalk and Dunn, 2005) after being log10 transformed:
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Where Y is the fluorescence measured in counts per second and Conc is the concentration of 
the reference standard in μM. The A parameter corresponds to the lower asymptote of the 
curve, the B parameter corresponds to the upper asymptote, the C parameter determines the 
midpoint concentration of the curve, the D parameter determines the slope of the curve at 
the midpoint, and the H parameter represents the degree of symmetry between the upper and 
lower halves of the curve. The curves displayed significant asymmetry between the upper 
and lower asymptotes, requiring the use of the 5-PL model rather than the symmetrical 4-
PL. The log10 transformation homogenized the variance across the range of the assay, and 
allowed the data to be fit without requiring additional weighting.
The observed reference standard data were fit to the 5-PL model using non-linear ordinary 
least squares in SAS® version 9.3 (SAS Institute Inc, Cary, NC). Sample concentrations, 
run in duplicate, were calculated by interpolating the mean of the duplicates to the standard 
curve using the measured sample fluorescence in counts per second.
The limit of detection was calculated as the minimum detectable concentration (MDC) and 
the limit of quantification was calculated as the reliable detection limit (RDL) (O'Connell et 
al., 1993; Quinn et al., 2002). The MDC is the concentration of PA83 or PA63 at which the 
five-PL-log fit of the standard curve data crosses the upper 95% confidence limit of the 
lower asymptote. The RDL is the concentration of PA83 or PA63 at which the lower 95% 
confidence limit of the 5-PL-log fit of the standard curve crosses the upper 95% confidence 
limit of the lower asymptote.
2.6. Precision and Accuracy for PA83 and PA63 Detection
Acceptable performance characteristics were based on published data for anti-PA IgG 
ELISAs (Semenova et al., 2012). Precision and accuracy of PA83 and PA63 detection were 
determined with TRF by spiking a known amount of PA into pooled sera and then 
calculating the measured concentration using a standard curve. The standard curve was 
produced by spiking pooled sera from 10 donors with 0.15 μM of PA83 or 0.75 μM of 
PA63. The master dilution of the spiked sera was then serially transferred in 3-fold dilutions 
to make a 14 point dilution series in pooled sera to ensure coverage of the dynamic range of 
the assay. Six dilution points, including points above and below the MDC and RDL, were 
run in duplicate on 10 independent runs on different days. The concentration of PA83 or 
PA63 in spiked sera samples was determined by interpolating the sample responses to the 
standard 5-PL curve fit as described in section 2.5.
Precision is a measurement of the degree of repeatability of an assay using standard 
operating procedures (FDA, 1996; FDA, 2001). Precision was expressed as the percent 
coefficient of variation (CV). An acceptable inter-assay precision would be a CV of ≤20%. 
Accuracy is a measure of the exactness of the assay and it was expressed as a percent error 
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between the assay-determined concentration and the known concentration for that serum 
(FDA, 1996; FDA, 2001). The percent error was calculated as the absolute value of 
[(observed − expected)/expected] × 100. An acceptable percent error was considered to be 
≤25%.
Dilutional linearity was calculated from the same raw data as accuracy and precision by 
linear regression of the observed concentrations against the spiked concentrations on log10 
scale. Linearity was evaluated by the slope, intercept and r-squared coefficient of the linear 
regression fit line. For this assay, acceptable linearity was considered to be 0.8 ≤ slope ≤ 1.2, 
−0.5 ≤ intercept ≤ 0.5, and r2 ≥ 0.85 (FDA, 2001).
2.7. Detection of PA83, PA63, and LTx clinical samples
The TRF assay method was followed for detection of PA only as described in section 2.4 
with PA83 as the standard. Undiluted sera samples from patients were tested in duplicate on 
a plate with 50 μl in each well. Concentration of PA in serum sample was determined by 
interpolating the sample responses to the standard 5-PL curve fit as described in section 2.5
2.8. Detection of PA63 and LTx in the presence of AIG
AIG is an adjunctive therapy for treatment of systemic anthrax and could impact the ability 
of the assay to detect PA. The effect of AIG on PA detection was evaluated by spiking AIG 
into sera with PA63 with and without LF. The standard curve was made by spiking pooled 
sera with PA63 at 0.75 μM or with LTx (7:4 ratio of PA63 to LF (0.75 μM PA63 and 0.43 
μM LF)). The master dilution mixes were then serially transferred in 3-fold dilutions to 
make a 10 point dilution series. PA63 was tested at two different concentrations 0.03 μM 
and 0.003 μM with and without LF (0.0171 μM or 0.00171 μM, respectively). The anti-PA 
IgG concentration present in AIG was determined by the ELISA (Semenova et al., 2012). 
AIG was added in a 50 molar excess of the PA63 concentration, 1.5 μM for PA63 at 0.03 
μM or 0.15 μM for PA63 at 0.003 μM of the PA63, and then serially transferred in a 3-fold 
dilution to make a 12 point dilution. Once the 12 point dilution of AIG was made PA63 or 
PA63 with LF was added to the appropriate tubes. Standard curves and experimental 
samples were run in duplicate on the plate. The IC50 of AIG was determined by plotting the 
observed CPS against the AIG concentration and fitting to a 4-parameter logistic (4-PL) 
model. The 4-PL was chosen instead of the 5-PL for this fit because there was insufficient 
resolution of the lower end of the curve to converge the 5-PL model.
3. Results
3.1. Monoclonal antibody selection and assay optimization
Monoclonal anti-PA antibodies AVR1046 and AVR1162 to PA83 and PA 63 were screened 
and selected on the basis of non-competitive binding to PA (data not shown). The anti-PA 
antibody pair on the TRF platform was able to detect PA63 in the presence of LF. Although 
there was a statistically significant reduction in signal point estimates (p < 0.01) the signal to 
background ratio for detection of PA63 was 150 at the lowest concentration of analyte 
evaluated (Fig. 1). When combining Eu-AVR1046 and Eu-AVR1674 to detect both PA63 
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and LF, there was an increase in signal compared to Eu-AVR1046 alone as the detector 
antibody. The increase was not statistically significant (p > 0.5).
3.2. Limit of detection and quantification
As described in section 2.5, the MDC and RDL were the calculated lower limits of detection 
(LOD) and quantification (LOQ), respectively, for this assay. MDC and RDL were 
calculated using the 95% confidence intervals of a five-parameter logistic-log 
transformation of the standard curve (Table 1). The MDC and RDL values for PA83 
detection were 2.69 × 10−6 μM and 6.63 × 10−6 μM, respectively (Fig 2). For PA63 
detection the MDC and RDL were and 9.17 × 10−6 μM and 2.51 × 10−5 μM, respectively 
(Table 1). The lower limit of detection of PA83 versus PA63 is indicated in the lower 
asymptote of PA83 detection curve (Fig 3).
3.3. Precision and accuracy for PA83 and PA63 detection
The precision of the assay was variable with CV values ranging from 20.8% to 189.7% for 
PA83 and from 8.2% to 133.2% for PA63 (Table 2). The average CV for PA63 was lower at 
45.0% compared to PA83 at 69.4%, but did not meet the acceptance criterion of ≤20%. The 
accuracy of the assay ranged from 4.7% to 156.2% for PA83 with 4 of 6 spiked 
concentrations having a percent error meeting the acceptance criterion of 25% (Table 2). 
The accuracy for PA63 was similar with a range from 9.0% to 58.4% with 4 of 5 
concentrations meeting the acceptance criterion (Table 2). PA83 demonstrated better 
dilutional linearity than PA63, with calculated r2 of 0.960 and 0.945, respectively. In 
addition, the two lowest concentrations of PA63 spiked into sera were censored in order to 
maintain linearity of the data (Fig. 3).
3.4. Detection of PA in clinical samples
PA concentrations were above the LOQ with a CV of <20% for 9 of 10 of the confirmed 
anthrax patients tested while none of the samples from healthy controls had PA levels 
greater or equal to the LOQ (Table 3). For the cutaneous anthrax cases the measured PA 
levels ranged from 1.02 ng/ml to 68.77 ng/ml (1.23 × 10−5 μM to 4.85 × 10−5 μM) (Table 3). 
The one sample that had PA levels less than the LOQ (6.63 × 10−6 μM) was from the only 
cutaneous case that had reportable levels of anti-PA IgG. The presence of endogenous anti-
PA may negatively affect the ability of the assay to detect PA (Table 3). There was no direct 
correlation between the time from onset of clinical signs and the amount of PA that was 
detected. The highest PA level was in the single patient with a sample taken one day after 
symptoms onset. For the inhalation and gastrointestinal anthrax cases the measured PA was 
greater than the LOQ in all samples tested (Table 3). The measured PA from sera of a 
patient with gastrointestinal anthrax and one of the inhalation cases were within the same 
range as was seen with the cutaneous cases, but both of these samples were drawn more than 
a week after onset of symptoms and the patient with inhalation anthrax had been on 
antimicrobial therapy for 6 days (Table 3). The highest levels of PA that were measured in 
all cases was from a sample taken only two days after the onset of symptoms and prior to 
antimicrobial treatment in a patient with inhalation anthrax (68.73 ng/ml) (Table 3). In 
contrast to the other inhalation case and the gastrointestinal case, this patient did not have 
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anti-PA IgG levels above the LLOQ. A linear correlation between the measured amount of 
LF and PA was found with a goodness of fit (mean R2) of 0.863 (Fig. 4).
3.5. Detection of PA63 and LTx in the presence of AIG
AIG was found to interfere with detection of PA63 and LTx. When the ratio of AIG to PA 
approached 1.1 to 3.6 (Figure 5) there was a 10% reduction in signal. A 50% reduction in 
signal was seen when AIG:PA ratio was 5.4:1 when the (0.03 μM PA) and 6.8:1 (0.003 μM 
PA).
4. Discussion
Early diagnosis and treatment of anthrax increases the likelihood of survival and recovery of 
the patient. Anthrax toxins are secreted early in the course of disease prior to detectable 
bacteremia or immune response and therefore provide a more timely diagnosis compared to 
serology or culture dependent methodologies. In rhesus macaque models of inhalation 
anthrax the onset of LF toxemia also precedes the detection of vegetative cell markers such 
as poly-D-glutamate capsule (Boyer et al., 2009). In the current study a europium based, 
time resolved fluorescence immunoassay (TRF) was used for the initial evaluation a library 
of anti-PA murine monoclonal antibodies that could also be used on other platforms to 
detect PA in spiked sera and sera from clinical anthrax patients. An antibody pair for capture 
(AVR1162) and detection (AVR1046) of PA were selected for their non-competitive 
binding to both PA83 and PA63 even in the presence of LF.
An assay for diagnosing anthrax through detection of PA must be able to detect both PA83 
and PA63, and it must be able to detect them in the presence of LF or EF. LF and EF are the 
proteolytic enzymes that are translocated by the PA63 oligomer to the host cell cytosol 
where they can then cause cytotoxic effects (Young and Collier, 2007). The binding of LF 
and/or EF to PA63 with sub-nanomolar affinity (Young and Collier, 2007) could potentially 
interfere with the ability of an assay to detect PA in clinical samples. It has been determined 
that three to four LF and/or EF can bind the PA63 complex (Young and Collier, 2007; 
Kintzer et al., 2009). In order to ensure that PA63 was saturated with LF, we spiked a ratio 
of seven PA63 with four LF in sera. Due to the commonalities of LF and EF interactions 
with the PA63 oligomer, we did not separately determine the effect of EF on the assay. The 
assay was able to detect PA63 in the presence of LF although there was a statistically 
significant decrease (p < 0.01) in signal. Thesignal to background ratio was still acceptably 
high at 150. The anti-LF mAb, AVR1674 did bind the LF as part of the LTx complex, but 
the increase in signal was not statistically significant. The ability to detect PA in the 
presence of LF is critical since the toxin complex would form in clinical samples from 
anthrax patients.
The calculated lower limit of quantification (LOQ), based on the reliable detection limit 
(RDL), in human sera was 6.63 × 10−6 μM (0.551 ng/ml) for PA83 and 2.51 × 10−5 μM 
(0.158 ng/ml) for PA63 with a calculated lower limit of detection (LOD), based on the 
MDC, of 2.66 × 10−6 μM (0.223 ng/ml) for PA83 and 9.17 × 10−6 μM (0.5578 ng/ml) for 
PA63. A previous study that used TRF reported the ability to detect PA in spiked mouse 
plasma at levels as low as 0.02 ng/ml, although this was not consistently reproducible at 
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levels as high as 0.04 ng/ml (Tang et al., 2009). The LOD was tenfold lower for Tang et al. 
(2009), although it was calculated using a linear fit while the current study used non-linear 
5-PL model. Differences in LOD could be due to the additional steps that they used to 
increase sensitivity while our method was based on a more traditional ELISA type assay so 
that we could evaluate performance of the mAbs for use on this and other platforms. Other 
assays for PA detection have included non-TRF fluorescence based assays (Oh et al., 2011; 
Dragan et al., 2012), electrochemiluminescence (Kobiler et al., 2006; Rossi et al., 2008) and 
traditional ELISAs (Kobiler et al., 2006; Mabry et al., 2006). Limits of detection of these 
assay ranged from 0.0001– 83 ng/mL, with the ELISA assays performing in the middle of 
the range. As with the Tang et al (2009) study, a limitation to comparing the performance of 
these assays is the variability in how the LOD was determined.
The precision of the TRF assay for detecting PA83 and PA63 was not optimal, with an 
average CV of 69.4% for PA83 and 45.0% for PA63. Only one dilution point had a CV < 
20% for PA63 and none for PA83. CV values this high are not desirable for quantitative 
analysis of clinical specimens, although we did see much better CV values when testing sera 
specimens from anthrax patients. For accuracy of detecting both PA83 and PA63 the % error 
was below 25%, which is acceptable for qualitative detection of an analyte. As mentioned 
previously, we found a lower RDL for PA83 detection compared to PA63 at 6.634 pM 
versus 25.107 pM, respectively. The ability to detect PA83 at lower concentrations than 
PA63 was also reflected in the accuracy experiments (Table 2, Fig. 3). Acceptable dilutional 
linearity for quantification of PA63 was only observed for four of the six spiked 
concentrations and the goodness of fit (mean R2) was lower for PA63 compared to PA83 
(Fig. 3). PA83 is activated by cleavage of a 20-kDa amino-terminal polypeptide (PA20) by a 
variety of serum and cellular proteases (Young and Collier, 2007). The conformational 
differences between PA63 after the loss of PA20 from PA83 could alter the ability of our 
capture and detector antibodies to bind, therefore lowering the detection limit. Variability in 
monoclonal antibody affinity for PA83 and PA63 has been demonstrated previously 
(Moayeri et al., 2007). The limitations of precision and accuracy on this platform may 
therefore limit the application of this approach to a qualitative ‘yes/no’ diagnostic test. In the 
context of high-throughput testing during an emergency, or for a point of care/point of need 
diagnostic setting, this is not necessarily a significant disadvantage, on condition that the 
diagnostic sensitivity and specificity remain high and the analytic sensitivity with precision 
is in the clinically relevant range.
To determine the performance of the assay in detecting PA as PA83, PA63, and LTx when 
testing clinical samples, sera samples from 10 case patients with confirmed anthrax were 
tested; 7 from patients with cutaneous anthrax; two from inhalation anthrax; and one from 
gastrointestinal anthrax. None of the patients had received AIG before samples were 
collected. PA levels above the LOQ were detected in all samples except for one, a sample 
drawn 8 days after onset of cutaneous anthrax in the only cutaneous patient with detectable 
anti-PA IgG. There was a positive correlation between PA and LF concentrations measured 
in sera from these patients (R2=0.854, Fig. 4). The sera from one of the inhalation anthrax 
cases estimated PA levels at greater than 6.0 × 10−4 μM or 68.73 ng/ml. This was the only 
non-cutaneous case tested that had a serum sample available that was drawn close to onset 
of symptoms.
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In the other eight patients tested, PA levels in sera were all less than 4.1 ng/ml. Six of the 
eight case patients with lower PA levels were diagnosed with cutaneous anthrax. The lower 
PA levels in these patients are likely due to the fact that cutaneous anthrax is generally a 
local infection and thus toxins are not as abundant in the blood system. Reports in the 
literature support this, with maximum LF levels in sera higher in an inhalation case (203.0 
ng/ml) compared to 26 cutaneous cases (1.264 ng/ml) (Walsh et al., 2007; Boyer et al., 
2011b). This perspective is also supported by immunologic data; persons with cutaneous 
anthrax had lower peak anti-PA IgG response with fewer memory B cells compared to 
patients with inhalation anthrax and it was proposed that this was due to the infection 
remaining locally (Quinn et al., 2004). The other two patients with low serum PA levels 
were diagnosed with either gastrointestinal or inhalation anthrax. The low PA levels in these 
patients were likely due to the timing of specimen collection. The serum samples tested from 
these patients were not drawn until more than one week after onset of symptoms and these 
patients had already begun to mount an immune response, evidenced by detectable anti-PA 
IgG antibody found in the sera. In addition, the patient with inhalation anthrax with low 
levels of PA had received appropriate antimicrobial therapy for anthrax beginning 6 days 
before the specimen was collected.
Another potential concern for detection of PA in clinical samples is if the patient had 
previously been treated with an immunotherapeutic such as Anthrax Immune Globulin 
(AIG, Cangene). AIG has been used for treatment of persons with anthrax under a FDA 
Emergency Investigational New Drug (E-IND) Protocol in the United States and other 
countries (Stern et al., 2008). AIG is derived from plasma from donors with antibody against 
PA due to anthrax vaccination and these anti-PA antibodies could compete with the 
antibodies used in the assay for binding to PA. In this study we found that the presence of 
AIG in spiked sera did interfere with the ability to detect PA63 and LTx. AIG caused a 50% 
decrease in signal when the concentration was around five to seven times greater than the 
PA63 concentration. The current therapeutic adult dose of AIG for treatment of anthrax, 
based on available data to date, is 420 U AIG or about 500 mg anti-PA IgG antibody. Using 
average human blood volume calculations (Feldschuh and Enson, 1977), this dose would be 
equivalent to about 94.0 μg/mL anti-PA IgG antibody in an adult male and 109.4 μg/mL 
anti-PA IgG antibody in an adult female. Based on our lower AIG:PA ratio of 5.4 to 1, the 
therapeutic anti-PA IgG antibody concentration would cause a 50% reduction in signal at 
PA concentrations just over 1.0 μM, a concentration much higher than the levels of PA 
detected in the patients with anthrax tested in this study (highest detected concentration was 
6.20 × 10−4 μM). Actual measured maximum concentration of anti-PA IgG antibody levels 
in patients treated with AIG ranged between 104.7 to 804.0 μg/ml, with values being much 
higher than the target concentration (Walsh et al., 2007)(unpublished data). These data 
suggest AIG will interfere in the ability of the assay to detect and measure PA levels. In 
patients that have been treated with AIG however, LF is still detectable up to seven days 
after treatment (Boyer et al., 2011b). Adding an additional assay for detection of LF and/or 
EF would be helpful in cases in which the patient has already been treated with AIG and 
monitoring of toxins levels is useful for patient management.
In this study, an anti-LF monoclonal antibody and an anti-PA monoclonal antibody pair 
were selected that can detect PA83, PA63, LF and LTx in serum. The ability to target 
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multiple epitopes in the toxin complex using combinations of anti-PA and anti-LF 
antibodies is an important facet of developing immunodiagnostic assays because the toxin 
conformation in serum may change depending on the stage of the infection. These data 
provide a basis for simple and efficient diagnostics for early stage anthrax – a significant 
advantage over the high sensitivity and specificity but high complexity approaches such as 
mass spectrometry. These antibodies are currently being evaluated for development of 
culture independent point-of-care assays to provide rapid, inexpensive and low complexity 
diagnosis of symptomatic anthrax.
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Fig. 1. 
Detection of PA63 in the presence of LF. Results of detection a 7:4 ratio of PA63 to LF (0.5 
μM PA63 and 0.286 μM LF) spiked in pooled sera from 10 donors. The master dilution mix 
was then serially transferred in 2-fold dilutions to make an 8 point dilution series in pooled 
sera. PA63 without LF with the equivalent 8 point dilution series was used as a control. Eu-
AVR1046 was used as the detector antibody as described in 2.4. The captured toxin was 
detected using 1.0 μg/mL Eu-AVR1046 and/or 2.0 μg/mL Eu-AVR1674. The curve is the 
mean ± standard error (SE) of 7 duplicate runs.
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Fig. 2. 
Graphic representation of minimum detectable concentration (MDC) and reliable detection 
limit (RDL). Figure shows the mean result of one run in duplicate of PA83 dilution series 
from 0.0000017 μM to 0.884 μM along with the 95% confidence interval and MDC and 
RDL.
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Fig. 3. 
Dilutional linearity of the time-resolved fluorescence (TRF) assay for PA using PA83 and 
PA63. Dilutional linearity determines the ability of an assay to obtain a result that is 
proportional to the concentration of the PA that is in the sample. Six samples with a range of 
concentration from 0.000002 to 0.02 μM for PA83 and 0.000009 to 0.02 μM for PA63 were 
used in the experiments. Data points below the lower limit of quantification for PA63 are 
not shown.
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Fig. 4. 
Comparative analysis of observed PA concentrations and LF concentrations in clinical 
cases. PA concentrations (μM) for a panel of 10 sera samples collected from human anthrax 
clinical cases were compared to previously measured LF concentrations (ng/ml) (Boyer et 
al., 2011b).
Stoddard et al. Page 17
J Immunol Methods. Author manuscript; available in PMC 2015 September 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 5. 
Detection of PA63 and lethal toxin (PA63 + LF) in the presence of anthrax immunoglobulin 
(AIG) at a concentration of (A) 0.03 μM PA63 (with and without 0.0171 μM LF) and (B) 
0.03 μM PA63 (with and without 0.00171 μM LF). AIG contains anti-PA antibodies and is 
used in treatment of patients with anthrax. A 50-fold molar excess of AIG was serially 
transferred in 3-fold dilutions to make an 11 point dilution series in sera starting at a 
maximum concentration of 1.5 μM. After the dilutions were completed, PA63 with and 
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without LF was added. The 4PL fit of Counts per Second versus the anti-PA IgG 
concentration (μM) is shown and IC50 and IC90 are given.
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Table 1
Limit of detection calculated as the minimum detectable concentration (MDC) and reliable detection limit 
(RDL) for PA83 or PA63 in pooled human sera.
PA83
( n=16)
PA63
( n=16)
MDC ± SD
(μM) 2.69 × 10−6 ± 2.25 × 10−6 9.17 × 10−6 ± 8.91 × 10−6
CV (%) 83.8 97.2
RDL ± SD
(μM) 6.63 × 10−6 ± 6.30 × 10−6 2.51 × 10−5 ± 2.73 × 10−5
CV (%) 94.9 108.6
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Table 2
Assessment of assay accuracy and precision for detecting PA83 and PA63. Assay was repeated in duplicate 10 
times (n) and for each the number of runs with a measurable results (nm), expected mean (μM) the observed 
mean (μM), standard deviation (St. dev), coefficient of variation (CV), and percent error (% error).a
Toxin Expected mean(μM) n m /n
Observed
mean (μM) St. dev
CV
(%) % Error
PA83 0 3/10 0.0000028 0.0000023 81.7 ND
0.000002 6/10 0.0000019 0.0000011 55.9 4.7
0.00001 9/10 0.000014 0.000026 189.7 37.7
0.001 10/10 0.0009 0.0002 20.8 11.8
0.005 10/10 0.0041 0.0013 31.8 18.4
0.01 10/10 0.012 0.005 41.2 23.5
0.02 9/10 0.051 0.04 77.2 156.2
PA63 0 0/10 ND ND ND ND
0.000009 0/10 ND ND ND ND
0.00003 3/10 0.00012 0.00002 133.2 58.4
0.008 10/10 0.0057 0.0005 8.2 23.4
0.02 10/10 0.022 0.005 23.9 9.0
0.05 10/10 0.055 0.018 32.7 10.5
0.2 3/10 0.15 0.04 27.0 24.5
aND = not determined
J Immunol Methods. Author manuscript; available in PMC 2015 September 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Stoddard et al. Page 22
Table 3
Performance of TRF assay in detecting PA as PA83, PA63, and toxin complex in clinical samples. Results of 
testing 100 μl sera from ten confirmed clinical cases (cutaneous, inhalation, and gastrointestinal) and ten 
healthy persons. Concentration was determined using a PA83 standard curve.a
Clinical Form
Time from Onset
to Sera Collection
(Days)
Lethal Factorb
(ng/ml)
anti-PA IgGc
(μg/ml)
TRF PA detection
Concenetration
(ng/ml)d
Coefficient of
Variation (CV)
(%)
Cutaneouse 8 0.996 <LLOQ 1.97 15.7
Cutaneouse 8 1.264 <LLOQ 1.02 14.8
Cutaneouse 7 0.310 <LLOQ 1.12 2.2
Cutaneouse 6 0.675 <LLOQ 1.70 17.3
Cutaneouse 1 <LOD <LLOQ 4.03 5.3
Cutaneouse 3 1.105 <LLOQ 1.89 1.3
Cutaneouse 5 0.035 4.0 <LLOQ NA
Inhalation 8 0.705 7.5 1.81 8.2
Inhalation 2 57.985 <LLOQ 68.73 2.2
Gastrointestinal 11 0.314 6.9 1.80 8.8
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
Healthy control NA NA <LLOQ <LLOQ NA
f
 37.5 μl per well instead of 50 μl of sera was tested, result was divided by 0.75 to adjust for this volume difference.
aNA = not applicable
b
Measured using mass spectrometry with a limit of detection (LOD) for lethal factor of <0.005 ng/ml (Boyer et al.,2007; Boyer et al., 2011a).
c
Measured using ELISA with a lower limit of quantification (LLOQ) for anti-PA IgG of ≤3.7 μg/ml (Semenova, 2012).
d
The limit of quantification (LOQ), based on the RDL, for PA is ≤0.551 ng/ml.
e
Lethal factor and anti-PA IgG data from Boyer et al., 2011b.
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